Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Trifluridine and Tipiracil Hydrochloride
Trifluridine and Tipiracil · 1 trial · 29 indications
All adverse events will be evaluated using Common Terminology Criteria for All Adverse Events (CTCAE) version (v.) 5.
Will utilize the keyboard design - a novel model- assisted dose-finding method to find the maximum tolerated dose
| Arm | Type | Description |
|---|---|---|
| Treatment Arm | EXPERIMENTAL | Patients receive trifluridine/tipiracil PO BID and talazoparib tosylate PO QD on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Trifluridine and Tipiracil Hydrochloride | DRUG | Given PO |
| Talazoparib Tosylate | DRUG | Given PO |
Inclusion Criteria: * Histologically or cytologically confirmed CRC or EGC adenocarcinoma that is locally advanced or metastatic (Cohort A); histologically or cytologically confirmed p53mt/RASonc (Cohort B1) or p53mt/RASwt CRC (Cohort B2) that is locally advanced or metastatic. Patients with adenoc...
Trifluridine and Tipiracil is an investigational small molecule being studied for the treatment of advanced malignant solid neoplasms, including locally advanced or metastatic colorectal cancer and gastroesophageal junction adenocarcinoma. It is currently in Phase 1 clinical development for these indications.
Trifluridine and Tipiracil is a small molecule combination therapy. Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, disrupting DNA synthesis, while tipiracil inhibits thymidine phosphorylase, preventing the breakdown of trifluridine. This combination is being studied for its antitumor activity.
Trifluridine and Tipiracil is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
Trifluridine and Tipiracil is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities for the treatment of advanced malignant solid neoplasms.
Trifluridine and Tipiracil is being studied in a Phase 1 clinical trial with the identifier NCT04511039. This trial is evaluating the combination of trifluridine/tipiracil and talazoparib in patients with locally advanced or metastatic colorectal or gastroesophageal cancer. The trial is currently recruiting participants in the United States.
Yes, Trifluridine and Tipiracil is also known as Trifluridine and Tipiracil Hydrochloride. Both names refer to the same investigational drug combination being developed by Pfizer, Inc.